View More Recent Stories

Oct 7, 2015 04:41PM Sandoz Canada launches PrSandoz(R) Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence
Oct 7, 2015 04:41PM Sandoz Canada launches PrSandoz(R) Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence
Sep 30, 2015 05:04PM Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Sep 27, 2015 06:02PM Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Sep 25, 2015 09:15AM Sandoz Canada Celebrates Its 10th Anniversary!
Sep 24, 2015 12:30PM Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Sep 2, 2015 04:11PM Health Canada Approves New Indications for PrOmnitrope(R) (Somatropin), Canada's First Subsequent Entry Biologic (Biosimilar)
Sep 2, 2015 04:11PM Health Canada Approves New Indications for PrOmnitrope(R) (Somatropin), Canada's First Subsequent Entry Biologic (Biosimilar)
Aug 24, 2015 07:07PM FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
Aug 20, 2015 04:42PM Sandoz Canada launches PrAmiodarone Syringe for the treatment of several heart rhythm disorders
Aug 20, 2015 04:42PM Sandoz Canada launches PrAmiodarone Syringe for the treatment of several heart rhythm disorders
Jul 7, 2015 04:50PM Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
Jun 11, 2015 06:31PM Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
Jun 1, 2015 04:07PM Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Jun 1, 2015 09:00AM Novartis presents new data at ASCO for Zykadia™ and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs
May 31, 2015 10:46AM Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
May 27, 2015 09:05AM Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA
May 20, 2015 11:45AM Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
Apr 24, 2015 06:15AM Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
Mar 30, 2015 07:03PM Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
Nov 14, 2012 01:15AM New survey finds women who suffer from migraines want a better understanding of migraine triggers
Sep 4, 2012 01:15AM Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Nov 7, 2011 01:15AM Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
View More Recent Stories